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Microsomal incubation test of potentially hemolytic drugs for 
glucose-6-phosphate dehydrogenase deficiency 
The in vitro metabolizing method was modified and its ability to correctly identify eight known 
hemolytic and nine known nonhemolytic drugs of glucose-6-phosphate (G6PD)deficient 
erythrocytes was evaluated. The technique is based on inducing in vitro drug metabolism by 
incubation of red cells and drug with a reduced NADPgenerating system in the presence of 
phenobarbital-induced mouse liver microsomes. Thus, this system provides a model for in vivo 
metabolic function. The hemolytic potential of tested drugs is indicated by the extent of loss of 
reduced glutathione of G6PD-deficient erythrocytes during 60-min incubations. Complete 
agreement between the test and literature for nonhemolytic compounds was observed. The test 
also correctly identified six of the eight known hemolytic drugs and failed to identify two known 
hemolytic drugs (acetanilide and sulfacetamide). The test was also applied to 14 drugs about 
which there is uncertainty regarding hemolytic potential. Of the latter, DL- a- methyldopa; 
a-naphthol; [3-naphthol; 2,3, dimercaptopropanol; phenacetin; and menadione were found to 
react positively. We conclude that this in vitro assay system will be useful in predicting which 
new drugs will be hemolytic in G6PD-deficient patients. 
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Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency is an inherited sex-linked abnormal- 
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ity involving the human erythrocyte.8 Mutant 
genes producing G6PD deficiency occur pri- 
marily in populations derived from tropical 
areas of the world. In the United States it occurs 
particularly in people of African or Mediterra- 
nean descent. These individuals are asymp- 
tomatic except when exposed to a drug that in- 
duces hemolytic anemia. Drugs causing diffi- 
culties are aminoquinoline antimalarials such as 
primaquine, some of the sulfonamides and ni- 
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trofurans, certain antipyretics and analgesics, 
sulfones, some vitamin K analogues, and cer- 
tain vegetable foods such as the fava bean.6' 36 
Since the enzyme deficiency is common, oc- 
curring with a gene frequency of about O. 11 in 
the black population of the United States ,6 and 
since some of the drugs are in common clinical 
use, the prediction of drug-induced hemolysis 
in G6PD-deficient individuals is of clinical im- 
portance. 
Many of the hemolytic drugs (e.g., prima- 
quine) are harmless to G6PD-deficient red cells 
in vitro but cause hemolysis in vivo, an obser- 
vation that indicates that metabolic conversion 
of the drugs to hemolytic intermediates may be 
necessary for hemolysis.7' 27' 36 This has made it 
difficult to establish, by in vitro techniques, 
which new drugs might be hemolytic to 
G6PD-deficient patients. Simple incubation of 
the drug with G6PD-deficient red cells, as de- 
scribed by Beutler, causes depletion of reduced 
glutathione (GSH) in only a minority of situ- 
ations in which the drug is known to be 
hemolytic in vivo.3 Three remaining methods of 
identification of hemolytic compounds have in- 
volved drug administration to human subjects. 
The first involves carefully controlled studies 
like those carried out by Dern et al." In the 
early years of investigation of G6PD deficiency 
they followed the survival of 31Cr-labeled 
G6PD-deficient red cells during drug use. A 
second involves measuring increased amounts 
of 14C-2 evolution and glucose utilization when 
erythrocytes from normal patients are incubated 
with glucose- 1-C" in serum after ingestion of 
hemolytic drugs."' 37 The third method of iden- 
tification of hemolytic compounds has involved 
case reports of hemolytic reaction encountered 
during clinical use. Relying on case reports is 
undesirable in that they involve exposure of pa- 
tients to an unknown risk before the danger is 
realized. Furthermore, it is often difficult to 
identify the specific drug causing hemolysis 
when many patients undergo multidrug therapy. 
In view of these problems, a dependable in vitro 
screening method is needed. 
An effective in vitro system to screen poten- 
tially hemolytic drugs must approximate the in 
vivo situation by including a metabolic model 
that generates the hemolytically active deriva- 
tives. Results from experimentation on hy- 
droxylated derivatives of dapsoneth' 23' 33 as 
well as studies of the peroxide-generating ca- 
pability of hydroxylated derivatives of 8-amino- 
quinolines" have implicated the role of in vivo 
N-hydroxylation on GSH depletion, methemo- 
globin production, and lysis of G6PD-deficient 
erythrocytes. We recently published a method 
for modeling the in vivo metabolism of drugs by 
an in vitro technique involving the generation of 
hydroxylated derivatives.27' 28 Briefly, this in- 
volves incubation of the drug under study with a 
mouse liver microsomal preparation (derived 
from mice) induced with phenobarbital. Addi- 
tional components of the system are a reduced 
NADP (NADPH)generating system and hu- 
man G6PD-deficient red cells, with nondefi- 
cient red cells used as controls. 
Results from this study indicated that in- 
creased hydroxylation activity of the mouse 
liver microsomes magnified the damaging effect 
of certain compounds.27' 28 These studies also 
indicated decreased damaging effect when acet- 
ylated compounds of dapsone or thiazolsulfone, 
two sulfones, were used. It had been shown that 
approximately half of the human population 
handle such sulfones in a way that makes them 
hemolytic .'3 Our findings that acetylated sul- 
fones are not damaging to G6PD-deficient cells 
explains the 25-year-old mystery of sulfone 
hemolytic bimodality. It is known that there is a 
genetic polymorphism affecting liver acetylation 
rates. About half of the population are fast 
acetylators, the other half slow. Fast acetylators 
would be relatively protected against hemolytic 
damage from sulfones, while slow acetylators 
would be vulnerable. Genetic variation in hy- 
droxylation, well established in mice," may also 
occur in man. Our study demonstrated for the 
first time that interaction between multiple phar- 
macogenetic systems could determine the pheno- 
typic outcome. In this case, interaction between 
hydroxylation, acetylation, and G6PD defi- 
ciency was involved. Interaction between acety- 
lation and G6PD deficiency has subsequently 
been confirmed by giving sulfamethazine to 
human subjects." 
The purpose of our study is to evaluate this 
in vitro microsomal system as a screening 
method for predicting the hemolytic potential of 
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drugs. The test system has been evaluated with 
the use of a series of drugs already known to be 
hemolytic as well as a series known to be 
nonhemolytic. The extent of positive correlation 
between GSH depletion in our study and the 
hemolytic or nonhemolytic predictions in the 
literature was evaluated to establish the degree of 
reliability of this method. A third series of po- 
tentially hemolytic drugs about which there is 
uncertainty was also studied. 
Methods 
The in vitro liver microsomal preparation was 
used as described." In brief, 5- to 7-wk old CD-1 
male mice from Charles River Company were 
fasted overnight and administered a drinking so- 
lution of sodium phenobarbital and sucrose for 5 
days. This procedure caused induction of the 
drug metabolizing systems in the microsomes. 
Livers were then homogenized from pooled 
fresh livers with cold O. 1M phosphate buffered 
saline (PBS), pH 7.4. The induction of liver 
microsomal hydroxylation activity of the pre- 
pared homogenate was estimated by Magon 
et al. '528 modification of Zannoni 's" spectro- 
photometric method for measuring p-nitroanis- 
ole-O-demethylase activity. 
The human G6PD-deficient (A-) red cells 
were freshly drawn, washed three times with 
cold normal saline, washed once with cold PBS, 
Table I. Classification of drugs, references, and solvents used to dissolve them in the 
incubation flasks 
Drug Solvent Reference Nos. 
A. Drugs known to be nonhemolytic in G6PD deficiency 
Aspirin Methanol 4 
p-Aminobenzoic acid Methanol 4, 13 
Chloroquine (diphosphate salt) PBS 4, 10, 15, 
Quinidine HC1 Methanol 26, 39 
Quinine SO4 Methanol 26, 39 
Sulfadiazine Methanol 4 
Sulfamerazine Acetone 4 
Sulfathiazole Acetone 4 
Tripelennamine PBS 4 
B. Drugs known to be hemolytic in G6PD deficiency 
Acetanilide Methanol 13 
Dapsone Methanol 12 
Naphthalene Acetone 19, 42 
Phenylhydrazine (hydrochloride) PBS 13, 24 
Primaquine (diphosphate) PBS 14, 22 
30, 39 
Sulfacetamide (sodium salt) Methanol 4, 13 
Sulfanilamide Methanol 4, 13, 39 
Sulfapyridine Acetone 13, 35, 39 
C. Possibly hemolytic compounds in G6PD deficiency 
Acetaminophen Methanol 
Aniline PBS 10, 15, 21 
2,3-Dimercaptopropanol Added directly 32 
DL-a-methyldopa PBS 5, 17, 25 
Menadione (sodium bisulfite salt) PBS 20, 39, 41 
Nalidixic acid Chloroform 2 
a-Naphthol Methanol 11,41 
13-Naphthol Methanol 34, 41 
Phenacetin Methanol 13 
Sulfaguanidine Methanol 
Sulfamethoxazole Methanol 1,9 
Succinylsulfathiazole PBS 
Sulfisomidine Methanol 
Sulfisoxazole Methanol 24 
24 
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Table II. Percent residual GSH and standardized drug effect of test drugs in experiments 
with and without induced microsomes 
and then resuspended to their original volume in 
PBS. 
The basic in vitro mouse microsomal incuba- 
tion system has been published." In brief, it 
consisted of a separate mixture for each test 
drive, which combined the suspension of the 
freshly prepared mouse liver microsome pellet, 
G6PD-deficient red cells, an NADPH generat- 
ing system (G6P, MgC12, NADP+, G6PD de- 
hydrogenase), and 1-mM final concentration of 
test drug when present. 
Chn. Pharmacol. Ther. 
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*For the most part, "known to be hemolytic or "nonhemolytic" refers to the hemolytic potential in G6PD deficiency of the A type (black 
population). 
The published method was modified for the 
purposes of this test as follows. The 3.7-ml in- 
cubations were scaled proportionately to 2.5 
ml. Instead of using normal erythrocytes or add- 
ing the hydroxylation inhibitor SKF-525A, the 
controls in this study included elimination of 
drug, or NADP+, or both from the incubation 
mixture. The drugs tested, the solvent in which 
they were dissolved just before incubation, and 
the references to their hemolytic or nonhemo- 
lytic nature are shown in Table I. All of the 
Drug tested 













A. Drugs known not to be hemolytic* 
Aspirin 4 73 ± 18 90 ± 11 
p-Aminobenzoic acid 4 77 ± 16 96 ± 6 
Chloraquine (diphosphate salt) 2 71 ± 12 87 ± 6 
Quinidine HC1 2 86 ± 23 99 ± 21 
Quinine SO4 2 56 ± 21 98 ± 9 
Sulfadiazine 3 75±7 100± 11 
Sulfamerazine 3 60±19 98 ± 10 
Sulfathiazole 2 55 ± 22 94 ± 11 
Tripelennamine 4 71 ± 8 90 ± 11 
B. Drugs known to be hemolytic* 
Dapsone 4 32 ± 9 44 ± 13 1 127 126 
Naphthalene 2 20 ± 1 26 ± 1 1 96 95 
Phenylhydrazine (hydrochloride) 5 23 ± 4 35 _± 8 1 27 28 
Primaquine (diphosphate salt) 2 57 ± 1 56 -± 1 3 93 ± 3 91 
Sulfanilamide 3 26 ± 9 42 ± 6 1 98 97 
20 Sulfapyridine 4 32 ± 14 45 -± 19 2 114 ± 18 111±2
Acetanilide 5 73 ± 8 93 ± 5 1 108 106 
Sulfacetamide (sodium salt) 4 66 ± 15 103 ± 3 2 99±2 2 96 ± 0 
C. Potential hemolytic drugs 
a-Naphthol 1 15 19 1 70 49 
(3-Naphthol 3 14 ± 3 24 ± 11 1 104 102 
Menadione (sodium bisulfite salt) 2 28 ± 1 50 ± 11 51 52 
Acetaminophen 4 64 ± 13 79 ± 5 
Aniline 4 58 ± 7 72 ± 5 
2,3-Dimercaptopropanol 2 15 ± 7 19 ± 7 
DL-a-methyldopa 2 50 ± 7 60 ± 8 
Nal idixic acid 2 78 ± 7 91 ± 4 
Phenacetin 3 38 ± 12 53 ± 12 
Sulfaguanidine 3 82 ± 14 101 ± 6 
Sulfamethoxazole 2 53 ± 5 95 ± 18 
Succinylsulfathiazole 2 55 ± 26 95 ± 18 
Sulfisomidine 3 73 ± 6 92 ± 6 
Sulfisoxazole 3 56 ± 23 86 ± 16 
D. Control (without drug) 
13 73 ± 13 3 102 ± 3 
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solvents except PBS were allowed to evaporate 
in the flask to leave a final test compound con- 
centration of 1 mM. (Note that 2,3-dimercap- 
topropanol was added directly.) 
GSH levels in each flask were measured by 
the spectrophotometric method of Prins and 
Loos31 at both the beginning and end of the 60 
min incubation period at 37°. The GSH remain- 
ing after 60 min incubation was expressed as 
percent of initial GSH, with the exception of 
three drugs (2,3-dimercaptopropanol, menadi- 
one [sodium bisulfite salt], and phenylhydrazine 
[HCI salt]). A rapid initial loss of GSH occurred 
with phenylhydrazine, making it impossible to 
determine the initial levels accurately. Similar 
difficulties were found with 2,3-dimercaptopro- 
panol and menadione with which there were 
extremely high initial readings, indicating some 
interference of the parent drug. Yet, a marked 
depletion of GSH was evident upon incubation. 
Thus, for these three drugs, the average initial 
GSH levels obtained from simultaneous incu- 
bations were used as estimates of basal GSH 
levels. To compare results between trials with 
different preparations, we have defined the test 
result as the ratio of percent residual GSH in the 
presence of the test agent divided by percent 
residual GSH in the absence of the test agent. 
Results 
The known nonhemolytic, known hemolytic, 
and possibly hemolytic compounds, along with 
references, are listed in Table I. We have used 
the drugs of known in vivo hemolytic potential 
(Table II, A and B) to evaluate our in vitro test 
system. The nine nonhemolytic drugs of Table 
II, A had mean test values between 87 and 100. 
Of these drugs, chloroquine (diphosphate salt) 
was found to have the lowest test result value 
(87, about 2 SDs above 70); this is the value we 
now tentatively define as the lower limit for 
nonhemolytic drugs. The results in Table II, B, 
including eight drugs known to be hemolytic in 
vivo, fell into two ranges; the first six listed 
have mean values between 26 and 56. The value 
of 70 as the upper limit for identifying hemo- 
lytic compounds serves to identify these six as 
hemolytic. The other two hemolytic drugs, 
acetanilide and sulfacetamide (sodium salt), had 
values of 93 and 103 which are in the range of 
the nonhemolytic drugs of Table II, A. Thus, 
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the value of 70, while empirically chosen, ap- 
pears to be a good dividing point between nor- 
mal and abnormal test results. 
If microsomes are not included, incubation of 
known hemolytic drugs with deficient red cells 
identified only one of these drugs (phenylhy- 
drazine; Table II, B). When the experimentally 
determined value of 70 is used to evaluate the 
potentially hemolytic drugs of Table II, C, we 
find that six of the 14 drugs had positive values 
indicative of hemolytic potential: 2,3-dimercap- 
topropanol, DL-a-methyldopa, a-naphthol, f3- 
naphthol, phenacetin, and menadione. 
When normal, rather than G6PD-deficient, 
red cells were used in the test system along with 
microsomes, only phenylhydrazine gave a pos- 
itive test result (data not shown). 
Discussion 
The principle of this new method for evaluat- 
ing the hemolytic potential of drugs is based on 
the hypothesis that most drugs are metabolized 
by the liver microsomal system and become ac- 
tivated to hemolytic intermediates. Indeed, only 
one of the eight known hemolytic drugs caused 
GSH depletion in the absence of the micro- 
somes (Table II, B): In the presence of micro- 
somes, the method proved fairly reliable in 
separating hemolytic from nonhemolytic drugs. 
A natural division appeared to occur at a test 
result of 70. All of the known normal drugs fell 
above this level. The two hemolytic drugs that 
fell above this level were well into the mid- 
range of the nonhemolytic drugs. Thus, we sus- 
pect that the metabolism of these two drugs is 
qualitatively different. It is possible that the me- 
tabolism of these drugs may not involve com- 
ponents available in the mouse microsomal sys- 
tem as it exists in our procedure. Test results for 
drugs of uncertain status (Table II, C) revealed 
that six of them (2,3-dimercaptopropanol, phen- 
acetin, menadione, a-naphthol, /3-naphthol, 
and DL-a-methyldopa) gave positive test results 
while the other eight gave negative results. Our 
test would predict that these drugs would be 
hemolytic in G6PD-deficient subjects. 
Based upon our results, we have identified a 
test result of 70 as the critical point between 
hemolytic and nonhemolytic compounds. It ap- 
pears so far that nonhemolytic drugs do not tend 
to give false-positive reactions, but that occa- 
sionally a hemolytic compound will give a 
false-negative result. In spite of these occa- 
sional results, we conclude that this test offers 
considerable advantage over other in vitro and 
in vivo methods for the identification of poten- 
tially hemolytic drugs, with a 75% success rate 
in correctly identifying hemolytic drugs in con- 
trast to the 12.5% (one of eight) success rate 
with incubation of the same test compounds and 
red cells without the induced microsomes. 
We recognize that the use of this test has 
certain theoretical limitations. First, it depends 
on the liver microsomes being the site at which 
the tested drugs are metabolized to their active 
metabolites, rather than other locations within 
the liver or body. Second, success depends on 
induced mouse liver microsomes serving as an 
adequate model for the human microsomal sys- 
tem. In spite of these considerations, the method 
seems to be relatively accurate, and this in vitro 
system affords the opportunity to screen many 
drugs simultaneously while avoiding the risk 
incurred by screening procedures that expose 
humans to the tested drugs.'3. 16' 37 
The 17 drugs that we used for standardization 
include most of the drugs on which extensive 
human studies have been performed. It remains 
to be seen whether these test results coincide 
with positive and negative results from actual 
clinical experience with new drugs. 
We thank Ms. Louisa La Farge and Ms. Marla 
Wohlman for their assistance. 
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